

# WIKINGO Project Systematic Analysis

## Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

## Contents

### List of Tables

1	Participant characteristics . . . . .	3
2	According to Local Recurrence . . . . .	4
3	According to Metastasis . . . . .	6
4	According to Exitus . . . . .	8
5	Incidence by outcome [95% CI] . . . . .	13

### List of Figures

1	Local Recurrence . . . . .	5
2	Metastasis . . . . .	7
3	Exitus . . . . .	9
4	Local Recurrence, according to Type of Resection: . . . . .	10
5	Metastasis, according to Type of Resection: . . . . .	11
6	Survival, according to Type of Resection: . . . . .	12

Table 1: Participant characteristics

	[ALL] N=199	N
Age	67.0 (11.3)	199
Sex: Men	130 (65.3%)	199
Tumor level:		199
0-6cm	67 (33.7%)	
7-12cm	114 (57.3%)	
13-15cm	18 (9.05%)	
Tumor stage:		199
0	23 (11.6%)	
I	55 (27.6%)	
II	59 (29.6%)	
III	62 (31.2%)	
Neoadjuvant treatment	124 (62.3%)	199
Type of resection:		199
Abdominoperineal resection	32 (16.1%)	
Anterior resection	135 (67.8%)	
Hartmann	32 (16.1%)	
Perforation	6 (3.02%)	199
Invasion circumferential margin	22 (11.1%)	199
Mesorecto quality:		198
Satisfactory	152 (76.8%)	
Partial	28 (14.1%)	
No-satisfactory	18 (9.09%)	
Recidive	16 (8.04%)	199
Months to recidive	30.0 [10.0;60.0]	199
Metastasis	31 (15.6%)	199
Months to Metastasis	26.0 [9.00;60.0]	199
Exitus	40 (20.1%)	199
Months to exitus	33.0 [11.0;60.0]	199


Table 2: According to Local Recurrence

	No event n= 183	Event n= 16	Crude HR	p-value	Multivariate HR	p-value
Age (10y)	6.71 (1.11)	6.58 (1.28)	1.02 [0.67;1.56]	0.916	0.84 [0.48; 1.47]	0.544
Sex: Men	123 (67.2%)	7 (43.8%)	0.44 [0.16;1.18]	0.104	0.30 [0.09; 0.98]	0.046
Tumor level:						
0-6cm	56 (30.6%)	11 (68.8%)	213916777 [0.00;.]	0.998	986130696.05 [0.00; Inf]	0.998
7-12cm	109 (59.6%)	5 (31.2%)	52209346 [0.00;.]	0.998	140659822.04 [0.00; Inf]	0.998
Tumor stage:						
0	22 (12.0%)	1 (6.25%)	0.52 [0.06;4.71]	0.565	0.77 [0.07; 8.69]	0.833
II	57 (31.1%)	2 (12.5%)	0.47 [0.09;2.57]	0.384	0.24 [0.03; 1.72]	0.156
III	53 (29.0%)	9 (56.2%)	1.87 [0.57;6.08]	0.299	0.65 [0.14; 2.97]	0.58
Neoadjuvant treatment	115 (62.8%)	9 (56.2%)	0.65 [0.24;1.75]	0.396	0.37 [0.10; 1.42]	0.149
Type of resection:						
Abdominoperineal resection	28 (15.3%)	4 (25.0%)	2.80 [0.82;9.59]	0.100	0.93 [0.16; 5.33]	0.931
Hartmann	27 (14.8%)	5 (31.2%)	4.99 [1.57;15.8]	0.006	6.17 [1.03; 36.91]	0.046
Perforation	5 (2.73%)	1 (6.25%)	3.33 [0.44;25.2]	0.245	7.18 [0.39;133.70]	0.186
Invasion circumferential margin	18 (9.84%)	4 (25.0%)	2.70 [0.87;8.38]	0.086	4.87 [0.97; 24.31]	0.054
Mesorecto quality:						
Partial	26 (14.3%)	2 (12.5%)	0.96 [0.21;4.29]	0.957	0.30 [0.04; 2.03]	0.217
No-satisfactory	16 (8.79%)	2 (12.5%)	1.35 [0.30;6.04]	0.696	0.50 [0.07; 3.75]	0.504

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	199	142	108	90	66	55


Table 3: According to Metastasis

	No event n= 168	Event n= 31	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.71 (1.15)	6.60 (0.97)	1.02 [0.76;1.38]	0.883	1.00 [0.71; 1.41]	1	199
Sex: Men	113 (67.3%)	17 (54.8%)	0.68 [0.33;1.38]	0.284	0.61 [0.29; 1.32]	0.21	199
Tumor level:							199
0-6cm	55 (32.7%)	12 (38.7%)	4.22 [0.55;32.5]	0.167	3.96 [0.36;43.14]	0.258	
7-12cm	96 (57.1%)	18 (58.1%)	3.29 [0.44;24.6]	0.247	5.30 [0.63;44.75]	0.126	
Tumor stage:							199
0	22 (13.1%)	1 (3.23%)	0.59 [0.07;5.28]	0.637	0.49 [0.05; 5.32]	0.559	
II	49 (29.2%)	10 (32.3%)	2.65 [0.83;8.46]	0.099	2.33 [0.66; 8.17]	0.186	
III	46 (27.4%)	16 (51.6%)	3.75 [1.25;11.2]	0.018	3.05 [0.94; 9.89]	0.063	
Neoadjuvant treatment	104 (61.9%)	20 (64.5%)	1.02 [0.49;2.12]	0.967	1.14 [0.48; 2.70]	0.762	199
Type of resection:							199
Abdominoperineal resection	25 (14.9%)	7 (22.6%)	2.02 [0.85;4.80]	0.113	1.98 [0.56; 6.98]	0.288	
Hartmann	27 (16.1%)	5 (16.1%)	1.72 [0.64;4.63]	0.286	1.02 [0.32; 3.28]	0.969	
Perforation	5 (2.98%)	1 (3.23%)	1.94 [0.26;14.2]	0.516	7.03 [0.66;75.25]	0.107	199
Invasion circumferential margin	13 (7.74%)	9 (29.0%)	3.84 [1.76;8.36]	0.001	3.23 [1.29; 8.05]	0.012	199
Mesorecto quality:							198
Partial	23 (13.8%)	5 (16.1%)	1.44 [0.54;3.84]	0.467	0.94 [0.33; 2.68]	0.901	
No-satisfactory	12 (7.19%)	6 (19.4%)	3.12 [1.25;7.77]	0.015	3.10 [1.07; 8.93]	0.037	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	199	133	102	80	58	51

Table 4: According to Exitus


	No event n= 159	Event n= 40	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.55 (1.13)	7.29 (0.88)	2.14 [1.47;3.10]	<0.001	2.00 [1.30; 3.08]	0.002	199
Sex: Men	107 (67.3%)	23 (57.5%)	0.76 [0.41;1.43]	0.400	0.56 [0.27; 1.15]	0.113	199
Tumor level:							199
0-6cm	53 (33.3%)	14 (35.0%)	4.55 [0.60;34.6]	0.144	3.74 [0.38;36.60]	0.257	
7-12cm	89 (56.0%)	25 (62.5%)	4.52 [0.61;33.4]	0.139	6.34 [0.80;50.21]	0.08	
Tumor stage:							199
0	21 (13.2%)	2 (5.00%)	0.56 [0.12;2.63]	0.461	0.52 [0.10; 2.79]	0.448	
II	44 (27.7%)	15 (37.5%)	1.84 [0.78;4.33]	0.165	1.00 [0.37; 2.68]	0.999	
III	47 (29.6%)	15 (37.5%)	1.60 [0.68;3.77]	0.284	1.06 [0.40; 2.80]	0.912	
Neoadjuvant treatment	104 (65.4%)	20 (50.0%)	0.52 [0.28;0.97]	0.041	0.64 [0.30; 1.37]	0.247	199
Type of resection:							199
Abdominoperineal resection	25 (15.7%)	7 (17.5%)	1.50 [0.64;3.52]	0.349	4.19 [1.01;17.42]	0.049	
Hartmann	21 (13.2%)	11 (27.5%)	3.46 [1.66;7.19]	0.001	3.86 [1.32;11.30]	0.014	
Perforation	4 (2.52%)	2 (5.00%)	2.22 [0.53;9.21]	0.273	6.90 [1.23;38.75]	0.028	199
Invasion circumferential margin	11 (6.92%)	11 (27.5%)	3.05 [1.52;6.10]	0.002	3.70 [1.55; 8.80]	0.003	199
Mesorecto quality:							198
Partial	23 (14.5%)	5 (12.8%)	0.92 [0.36;2.36]	0.858	0.26 [0.09; 0.78]	0.016	
No-satisfactory	15 (9.43%)	3 (7.69%)	0.75 [0.23;2.46]	0.637	0.23 [0.06; 0.93]	0.039	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory




Figure 3: Exitus




Months	0	12	24	36	48	60
N:	199	144	113	93	67	58

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	32	21	17	15	9	8
Ant	135	106	82	71	52	42
H	32	17	9	6	5	5

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	32	17	14	12	7	6
Ant	135	101	80	66	46	40
H	32	17	8	5	5	5

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	32	21	18	17	9	9
Ant	135	107	85	73	53	44
H	32	18	10	6	5	5

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	3.03 [5.62; 0.38]	9.67 [14.08; 5.03]	9.09 [13.26; 4.72]
23	8.28 [12.71; 3.64]	14.87 [20.37; 9]	17.41 [23.14; 11.26]
36	9.15 [13.82; 4.22]	18.45 [24.64; 11.76]	21.4 [27.73; 14.52]
47	10.23 [15.27; 4.89]	21.89 [28.81; 14.29]	25.27 [32.22; 17.62]
60	12.99 [19.06; 6.48]	23.24 [30.46; 15.26]	28.8 [36.34; 20.37]